The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in ...

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...